Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management

Aziz A. A. Alnakli; Abidali Mohamedali; Benjamin Heng; Charles Chan; Joo-Shik  Shin; Michael Solomon; Pierre H. Chapuis; Gilles J. Guillemin; Mark S. Baker; Seong Beom Ahn

doi:10.1038/s44276-024-00043-z

Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management

Aziz A. A. Alnakli, Abidali Mohamedali, Benjamin Heng, Charles Chan, Joo-Shik Shin, Michael Solomon, Pierre H. Chapuis, Gilles J. Guillemin, Mark S. Baker, Seong Beom Ahn^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

73 Downloads (Pure)

Abstract

Colorectal cancer (CRC) poses a significant threat to many human lives worldwide and survival following resection is predominantly stage dependent. For early-stage cancer, patients are not routinely advised to undergo additional post-operative adjuvant chemotherapy. Acceptable clinical management guidelines are well established for patients in pTNM stages I, III and IV. However, recommendations for managing CRC stage II patients remain controversial and many studies have been conducted to segregate stage II patients into low- and high-risk of recurrence using genomic, transcriptomic and proteomic molecular markers. As proteins provide valuable insights into cellular functions and disease state and have a relatively easy translation to the clinic, this review aims to discuss potential prognostic protein biomarkers proposed for predicting tumour relapse in early-stage II CRC. It is suggested that a panel of markers may be more effective than a single marker and further evaluation is required to translate these into clinical practice.

Original language	English
Article number	13
Pages (from-to)	1-10
Number of pages	10
Journal	BJC reports
Volume	2
Issue number	1
DOIs	https://doi.org/10.1038/s44276-024-00043-z
Publication status	Published - 13 Jan 2024

Bibliographical note

Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1038/s44276-024-00043-zLicence: CC BY

Publisher version (open access)Final published version, 875 KBLicence: CC BY

Cite this

@article{36c970569d924613a9c2f38172c45f45,

title = "Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management",

abstract = "Colorectal cancer (CRC) poses a significant threat to many human lives worldwide and survival following resection is predominantly stage dependent. For early-stage cancer, patients are not routinely advised to undergo additional post-operative adjuvant chemotherapy. Acceptable clinical management guidelines are well established for patients in pTNM stages I, III and IV. However, recommendations for managing CRC stage II patients remain controversial and many studies have been conducted to segregate stage II patients into low- and high-risk of recurrence using genomic, transcriptomic and proteomic molecular markers. As proteins provide valuable insights into cellular functions and disease state and have a relatively easy translation to the clinic, this review aims to discuss potential prognostic protein biomarkers proposed for predicting tumour relapse in early-stage II CRC. It is suggested that a panel of markers may be more effective than a single marker and further evaluation is required to translate these into clinical practice.",

author = "Alnakli, {Aziz A. A.} and Abidali Mohamedali and Benjamin Heng and Charles Chan and Joo-Shik Shin and Michael Solomon and Chapuis, {Pierre H.} and Guillemin, {Gilles J.} and Baker, {Mark S.} and Ahn, {Seong Beom}",

note = "Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2024",

month = jan,

day = "13",

doi = "10.1038/s44276-024-00043-z",

language = "English",

volume = "2",

pages = "1--10",

journal = "BJC reports",

issn = "2731-9377",

publisher = "Springer, Springer Nature",

number = "1",

}

TY - JOUR

T1 - Protein prognostic biomarkers in stage II colorectal cancer

T2 - implications for post-operative management

AU - Alnakli, Aziz A. A.

AU - Mohamedali, Abidali

AU - Heng, Benjamin

AU - Chan, Charles

AU - Shin, Joo-Shik

AU - Solomon, Michael

AU - Chapuis, Pierre H.

AU - Guillemin, Gilles J.

AU - Baker, Mark S.

AU - Ahn, Seong Beom

N1 - Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2024/1/13

Y1 - 2024/1/13

N2 - Colorectal cancer (CRC) poses a significant threat to many human lives worldwide and survival following resection is predominantly stage dependent. For early-stage cancer, patients are not routinely advised to undergo additional post-operative adjuvant chemotherapy. Acceptable clinical management guidelines are well established for patients in pTNM stages I, III and IV. However, recommendations for managing CRC stage II patients remain controversial and many studies have been conducted to segregate stage II patients into low- and high-risk of recurrence using genomic, transcriptomic and proteomic molecular markers. As proteins provide valuable insights into cellular functions and disease state and have a relatively easy translation to the clinic, this review aims to discuss potential prognostic protein biomarkers proposed for predicting tumour relapse in early-stage II CRC. It is suggested that a panel of markers may be more effective than a single marker and further evaluation is required to translate these into clinical practice.

AB - Colorectal cancer (CRC) poses a significant threat to many human lives worldwide and survival following resection is predominantly stage dependent. For early-stage cancer, patients are not routinely advised to undergo additional post-operative adjuvant chemotherapy. Acceptable clinical management guidelines are well established for patients in pTNM stages I, III and IV. However, recommendations for managing CRC stage II patients remain controversial and many studies have been conducted to segregate stage II patients into low- and high-risk of recurrence using genomic, transcriptomic and proteomic molecular markers. As proteins provide valuable insights into cellular functions and disease state and have a relatively easy translation to the clinic, this review aims to discuss potential prognostic protein biomarkers proposed for predicting tumour relapse in early-stage II CRC. It is suggested that a panel of markers may be more effective than a single marker and further evaluation is required to translate these into clinical practice.

U2 - 10.1038/s44276-024-00043-z

DO - 10.1038/s44276-024-00043-z

M3 - Review article

C2 - 39516345

SN - 2731-9377

VL - 2

SP - 1

EP - 10

JO - BJC reports

JF - BJC reports

IS - 1

M1 - 13

ER -

Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this